Table 1.
Clinical summary of the reference cohort
| Diagnosis | n | ∅ age at surgery | ∅ age at onset | ∅ duration | Sex (female/male) |
|---|---|---|---|---|---|
| FCD 1A | 12 | 9.3 (± 4.6) | 2.2 (± 3.1) | 6.8 (± 4.3) | 7/5 |
| FCD 2A | 29 | 14.7 (± 11.5) | 3.5 (± 4.1) | 11.2 (± 10.2) | 13/16 |
| FCD 2B | 29 | 18.5 (± 14.6) | 3.6 (± 4.0) | 14.5 (± 12.2) | 13/16 |
| FCD 3A | 14 | 45.0 (± 19.7) | 9.4 (± 11.2) | 31.3 (± 21.0) | 9/5 |
| FCD 3B | 11(15) | 34.5 (± 14.7) | 26.6 (± 16.7) | 7.91 (± 8.8) | 6/5 |
| FCD 3C | 17 | 23.5 (± 18.9) | 15.1 (± 14.6) | 7.6 (± 8.9) | 6/11 |
| FCD 3D | 15 | 15.4 (± 11.0) | 5.7 (± 8.4) | 6.8 (± 5.4) | 7/8 |
| PMG | 33 | 8.5 (± 9.1) | 1.6 (± 2.7) | 5.9 (± 6.4) | 10/23 |
| HME | 6 | 1.3 (± 0.5) | 0.1 (± 0.2) | 1.3 (± 0.6) | 2/4 |
| TSC | 19 | 5.5 (± 6.9) | 0 (± 0) | 5.5 (± 6.9) | 8/11 |
| mMCD | 28 | 24.6 (± 17.6) | 9.6 (± 12.3) | 11.6 (± 13.3) | 13/15 |
| MOGHE | 22 | 8.0 (± 7.2) | 8 (± 7.3) | 6.0 (± 5.8) | 8/12 |
| TLE | 15 | 37.0 (± 15.3) | 7.4 (± 7.9) | 29.6 (± 16.6) | 8/7 |
| CTRL | 4(11) | 31.3 (± 22.3) | n.a | n.a | 3/1 |
CTRL control, HME hemimegalencephaly, FCD focal cortical dysplasia, mMCD mild malformation of cortical development, MOGHE mMCD with oligodendroglial hyperplasia in epilepsy, PMG polymicrogyria, TLE temporal lobe epilepsy, TSC tuberous sclerosis complex, n.a. not applicable